Fredun Pharmaceuticals Limited (BOM:539730)
India · Delayed Price · Currency is INR 1,472.90
-31.95 (-2.12%)
At close: Jan 21, 2026
Fredun Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 5,303 | 4,517 | 3,466 | 2,743 | 2,217 | 1,316 | Upgrade |
Other Revenue | 3.75 | 21.11 | 15.79 | 3.34 | 27.23 | 22.64 | Upgrade |
| 5,306 | 4,538 | 3,482 | 2,747 | 2,245 | 1,338 | Upgrade | |
Revenue Growth (YoY) | 35.96% | 30.35% | 26.75% | 22.37% | 67.74% | 18.74% | Upgrade |
Cost of Revenue | 4,049 | 3,499 | 2,757 | 2,191 | 1,843 | 1,070 | Upgrade |
Gross Profit | 1,257 | 1,039 | 724.71 | 555.79 | 401.99 | 268 | Upgrade |
Selling, General & Admin | 605.98 | 513.49 | 344.89 | 278.02 | 252.54 | 177.37 | Upgrade |
Other Operating Expenses | -13.56 | -12.02 | -1.12 | -1.97 | 7.33 | -1.54 | Upgrade |
Operating Expenses | 654.83 | 551.87 | 381.73 | 304.14 | 284.58 | 195.88 | Upgrade |
Operating Income | 602.64 | 487.33 | 342.99 | 251.65 | 117.41 | 72.12 | Upgrade |
Interest Expense | -254.63 | -204.24 | -125.18 | -75.62 | -43.91 | -38.4 | Upgrade |
Interest & Investment Income | 2.67 | 2.67 | 0.14 | 0.23 | 0.06 | 0.25 | Upgrade |
Currency Exchange Gain (Loss) | 9.82 | 9.82 | 7.19 | 13.85 | 11.81 | 0.55 | Upgrade |
Other Non Operating Income (Expenses) | 2.06 | -19.53 | -10.62 | -15.94 | 0.64 | -2.46 | Upgrade |
EBT Excluding Unusual Items | 362.56 | 276.05 | 214.52 | 174.18 | 86 | 32.07 | Upgrade |
Gain (Loss) on Sale of Assets | -1.12 | -1.12 | - | - | - | - | Upgrade |
Other Unusual Items | - | - | - | - | - | -11.64 | Upgrade |
Pretax Income | 361.44 | 274.94 | 214.52 | 175.09 | 86 | 32.07 | Upgrade |
Income Tax Expense | 86.11 | 77.54 | 58.29 | 67.02 | 22.65 | 11.92 | Upgrade |
Net Income | 275.34 | 197.39 | 156.23 | 108.07 | 63.35 | 20.15 | Upgrade |
Net Income to Common | 275.34 | 197.39 | 156.23 | 108.07 | 63.35 | 20.15 | Upgrade |
Net Income Growth | 55.66% | 26.34% | 44.57% | 70.58% | 214.45% | 5.93% | Upgrade |
Shares Outstanding (Basic) | 5 | 5 | 5 | 4 | 4 | 4 | Upgrade |
Shares Outstanding (Diluted) | 5 | 5 | 5 | 4 | 4 | 4 | Upgrade |
Shares Change (YoY) | -0.49% | - | 3.66% | 7.85% | 4.06% | 0.01% | Upgrade |
EPS (Basic) | 59.30 | 42.52 | 33.66 | 24.13 | 15.26 | 5.05 | Upgrade |
EPS (Diluted) | 59.30 | 42.52 | 33.66 | 24.13 | 15.26 | 5.05 | Upgrade |
EPS Growth | 56.42% | 26.34% | 39.48% | 58.14% | 202.19% | 5.92% | Upgrade |
Free Cash Flow | 172.32 | -351.69 | -80.78 | -239.03 | -66.66 | -12.18 | Upgrade |
Free Cash Flow Per Share | 37.12 | -75.76 | -17.40 | -53.38 | -16.05 | -3.05 | Upgrade |
Dividend Per Share | 0.700 | 0.700 | 0.700 | 0.700 | 0.700 | 0.700 | Upgrade |
Dividend Growth | - | - | - | - | - | 6.06% | Upgrade |
Gross Margin | 23.70% | 22.90% | 20.82% | 20.23% | 17.91% | 20.03% | Upgrade |
Operating Margin | 11.36% | 10.74% | 9.85% | 9.16% | 5.23% | 5.39% | Upgrade |
Profit Margin | 5.19% | 4.35% | 4.49% | 3.93% | 2.82% | 1.51% | Upgrade |
Free Cash Flow Margin | 3.25% | -7.75% | -2.32% | -8.70% | -2.97% | -0.91% | Upgrade |
EBITDA | 663.79 | 536.47 | 380.41 | 279.3 | 138.74 | 91.94 | Upgrade |
EBITDA Margin | 12.51% | 11.82% | 10.93% | 10.17% | 6.18% | 6.87% | Upgrade |
D&A For EBITDA | 61.16 | 49.14 | 37.42 | 27.65 | 21.33 | 19.82 | Upgrade |
EBIT | 602.64 | 487.33 | 342.99 | 251.65 | 117.41 | 72.12 | Upgrade |
EBIT Margin | 11.36% | 10.74% | 9.85% | 9.16% | 5.23% | 5.39% | Upgrade |
Effective Tax Rate | 23.82% | 28.20% | 27.17% | 38.28% | 26.33% | 37.17% | Upgrade |
Revenue as Reported | 5,353 | 4,563 | 3,491 | 2,765 | 2,261 | 1,353 | Upgrade |
Advertising Expenses | - | - | 11 | 0.99 | 4.58 | 1.57 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.